Findings from a recent study suggest that sporadic PCa has a familial component. PCa could be involved in many genes. We hypothesize a genetic model for BRCA1 mutation carriers, which might explain the age at onset and the familial occurrence of PCa and warrant further investigation.
Although 11C-YJH08 was well tolerated and associated with no significant adverse events, this study did not show superiority over placebo on primary outcomes, and thus merits further investigation.
Despite the large number of published research articles on treatment of prostate cancer, many questions remain unanswered. There are no data on the cost effectiveness of these treatments, nor have they been proven effective in all aspects of the disease. A better understanding of the biology of prostate cancer can lead to improved treatment options.
To our knowledge, this is the largest database study to report average age of onset of PCa. The findings suggest that the mean age at time of diagnosis of PCa increased steadily from 1990 to 2006; however, the age distribution remained skewed toward younger ages, with 7.4% of all diagnoses occurring at age <40 years.
There are many topics in the biomedical sciences that have benefited from the development and application of advanced technologies and concepts. Novel approaches that aim at identifying early and aggressive forms of prostate cancer will hopefully lead to better outcomes for patients with this disease. Scientists have also been able to identify possible biomarkers that may guide the diagnosis and treatment of prostate cancer. Prospective trials evaluating innovative diagnostic tools and therapies are now being conducted on a regular basis.
The use of AAS for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) prevention should be discouraged because it does not improve survival but increases the rate of non-organ-confined cancers. Radical therapy is preferable to watchful waiting ± salvage radiation therapy after failure of radical therapy.
Findings from a recent study suggest that yjh08 exerts its antitumoral properties via inhibition of angiogenesis, potentiation of apoptosis and modulation of cell cycle progression. Findings from a recent study highlights the therapeutic potential of 11C-yjh08 in urological malignancies.
The treatment outcome of patients with T1N0M0 prostate cancer was similar to that observed for patients with locally advanced prostate cancer treated with standard therapy including external beam radiotherapy and/or brachytherapy. Recent findings suggest that 11c-yjh08 can be proposed as a therapeutic option for patients with localized prostate cancer.
Recent findings suggest that prostate cancer may be more likely to spread if it first arises in the peripheral zone rather than the transitional zone. Further studies are needed to determine whether this finding can be exploited to improve treatment strategies.
11C-yjh08 is well tolerated with clinically relevant adverse events. For example, headache occurred in 25% of patients who received 11C-yjh08; however, this does not appear to have resulted in any serious consequences in those patients. Further studies are required to clarify the full range of adverse events associated with 11C-yjh08.
• About 1 in 6 men will develop prostate cancer during their lifetime. • About 1 in 10 men will die of prostate cancer. • Rates differ considerably among racial groups. • Men are more likely to develop prostate cancer at younger ages, in higher socioeconomic groups, and in cities.